Semax: What It Is, Where to Get It Prescribed, and What It Costs

Semax is a heptapeptide — seven amino acids, sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four are positions 4 to 7 of adrenocorticotropic hormone (ACTH), the pituitary hormone that tells the adrenal glands to make cortisol. The last three, Pro-Gly-Pro, are not part of ACTH; they were added to slow the peptide's breakdown in the body.

The point of the design is what was left out. Full-length ACTH raises cortisol and stimulates pigment cells; the 4–10 region had been studied for decades for its effects on attention and learning in animals, separately from any hormonal action. Semax keeps that region and is described in the literature as devoid of corticotropic and melanotropic activity — it is not expected to raise cortisol, and it is not a steroid, an anabolic agent or a stimulant.

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and that provenance shapes its evidence base. It is a registered medicine in Russia, sold there as nasal drops, and has been used in Russian neurology for acute ischaemic stroke and chronic cerebrovascular disease since the 1990s. Almost all of the clinical work was done in Russian hospitals and published in Russian-language journals, several with English abstracts on PubMed; the animal and cell work is more often in English.

That does not make the research worse or better. It does mean a compound with real clinical history in one country and very little clinical study in this one, and the FDA's July 2026 review turned on exactly that gap.

It is not a stimulant and does not work like one, and it is not a substitute for prescribed ADHD treatment. It is not a treatment for stroke in the United States; nothing on this page is a reason to delay emergency care. And it is not an anxiolytic — that is closer to the territory of Selank, a different peptide from the same research programme.

The most cited mechanism. A 2006 paper in Brain Research reported that a single application of Semax in rats increased BDNF protein and TrkB receptor phosphorylation in the hippocampus, and that treated animals showed more conditioned avoidance responses. BDNF is the growth factor most closely tied to synaptic plasticity and new memory formation, so this is the finding the "cognitive" label rests on. It is a rat finding.

A 2010 paper in Cellular and Molecular Neurobiology extended that to the injured brain: in rats with a permanent middle cerebral artery occlusion, Semax increased transcription of BDNF, NGF and their receptors in the ischaemic cortex, and did so selectively in ischaemic tissue rather than the healthy brain. This is the proposed basis for the neuroprotection claim — more growth-factor signalling where cells are under threat.

A 2014 genome-wide study in BMC Genomics looked at the whole transcriptome of the ischaemic rat cortex after Semax. The largest effect was not on neurons directly but on immune-response genes — chemokines and immunoglobulins in particular — with a smaller set of vascular genes. A 1999 clinical-immunological study in stroke patients from the Korsakov Journal reported a related shift toward anti-inflammatory mediators. The 2014 authors proposed that immune modulation and vascular support, rather than a single neuronal target, are the core of what the peptide does in ischaemia.

Animal work describes Semax increasing serotonergic signalling, and its analgesic effect in rodents was not blocked by naloxone, so it does not appear to act through opioid pathways. A separate mouse study reported that Semax potentiated amphetamine-induced dopamine release in the striatum — one of the reasons the FDA's reviewers were cautious, even though no human signal of that kind has been reported.

A 2024 paper in the European Journal of Pharmacology tested Semax in rats exposed to chronic unpredictable stress. Daily low-dose treatment counteracted the stress-induced loss of sucrose preference (an anhedonia measure), adrenal enlargement and the fall in hippocampal BDNF, which the authors framed as antidepressant-like activity through the stress axis. It is a male-rat study: mechanism, not a treatment claim.

This is the indication Semax was built for and the largest body of human work. A 1997 controlled clinical study in the Korsakov Journal of Neurology and Psychiatry compared 30 patients in the acute phase of hemispheric ischaemic stroke, given intranasal Semax alongside standard intensive care, with 80 conventionally treated patients matched for severity and location. The authors reported faster regression of general cerebral and focal deficits, particularly motor, on clinical rating scales, EEG mapping and somatosensory evoked potentials.

A 2018 clinical trial from the same group followed 110 patients after ischaemic stroke, split into early and late rehabilitation groups, each with and without Semax. Plasma BDNF rose in the Semax subgroups and stayed elevated, and the authors reported faster improvement and better final Barthel Index scores (a measure of independence in daily activities) in patients who received it.

A 2005 evaluation study, also in the Korsakov Journal, examined 187 patients at different stages of chronic cerebrovascular insufficiency and reported clinical improvement, stabilisation of disease progression, fewer strokes and transient ischaemic attacks during follow-up, and good tolerability including in older patients. It is a comparative study rather than a randomised one.

A 2000 controlled clinical study in Vestnik Oftalmologii compared patients with vascular, toxic, inflammatory and atrophic optic nerve conditions given intranasal Semax alongside standard therapy against a control group, reporting better visual acuity, visual field and electrophysiological measures in the treated groups. A 2001 paper reported similar findings in glaucomatous optic neuropathy. These are small, unblinded series.

A 2018 paper in the Bulletin of Experimental Biology and Medicine gave 14 healthy adults a single intranasal dose of Semax and measured changes in the brain's default mode network on functional MRI. That is a mechanistic study, not a performance trial. There is no published randomised trial of Semax for attention, memory or productivity in healthy people — worth saying plainly, because that is the use most people in the US are reading about.

A 1996 open-label Russian study gave a single intranasal dose to 37 adults with migraine or facial pain. A third of the migraine patients reported their headache resolved within two hours; the typical trigeminal neuralgia patients showed no change. The FDA's 2026 review concluded the study did not support effectiveness for either condition.

This is the part to understand before starting. There are no randomised, placebo-controlled trials of Semax published in English-language, peer-reviewed journals. What exists is a body of Russian clinical studies — some controlled, most open-label, several over a hundred patients — in stroke, chronic cerebrovascular disease and optic nerve disease, nearly all using the intranasal product registered there. The FDA's July 2026 evaluation excluded those studies not because they were judged poor, but because complete English translations were not supplied; on the material it could read it found insufficient evidence of effectiveness for the nominated uses.

The honest framing is therefore: registered and used clinically in Russia for neurological indications for thirty years; a coherent preclinical mechanism around BDNF, neurotrophins and immune modulation; and no Western-standard trial evidence for any indication, least of all cognitive enhancement in healthy adults. Any source describing Semax as "clinically proven" is overstating it.

• It does not establish an effect on memory, focus or attention in healthy adults. No trial has measured that.
• It does not establish an effect size or a timeline for any indication in a US population.
• It does not establish equivalence between the intranasal route of the Russian studies and subcutaneous injection; the FDA found no published pharmacokinetic work on subcutaneous Semax.
• It does not establish long-term safety over years of continuous use.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything in the United States.

Most people report nothing dramatic. Some describe mild alertness or clearer thinking on dosing days, which is not evidence of anything lasting. Some notice nothing, which is normal.

If there is an effect on mood or sustained attention it is usually described in this window, which is why a vial is sized at four weeks of weekday dosing. Prescribers describe it as a background change rather than an event — easier to start tasks, less mental fatigue late in the day — which is the kind of change that is easy to overattribute. A simple log is more useful than memory.

The weekday schedule is a prescriber convention, not a trial design: it keeps total exposure modest and builds in a regular break, given that long-term data does not exist. Your directions will say what your physician has chosen.

There is no withdrawal or rebound described in the literature. Whether anything persists is unknown; the Russian follow-up data is in patients with brain injury, not healthy adults.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe, which at 2 mg/mL is 0.5 mg of Semax per dose. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. There is no "near the injury" logic here; the target is the brain and the route is systemic. The Russian product is nasal drops and the clinical studies used that route; the compounded prescription here is an injection, and published pharmacokinetic work on subcutaneous Semax has not been identified. That is one of the honest gaps on this page.

20 doses at once daily, Monday through Friday, is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. Keep it in the fridge between doses rather than on the counter.